Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-926-5251
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees50
Next Earnings Date2/24/2020 (Estimated)
OptionableNot Optionable
Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions
What is Turning Point Therapeutics' stock symbol?
Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."
How were Turning Point Therapeutics' earnings last quarter?
Turning Point Therapeutics (NASDAQ:TPTX) posted its earnings results on Monday, November, 4th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.04. View Turning Point Therapeutics' Earnings History.
When is Turning Point Therapeutics' next earnings date?
What price target have analysts set for TPTX?
10 brokers have issued 1 year price targets for Turning Point Therapeutics' stock. Their forecasts range from $42.00 to $70.00. On average, they expect Turning Point Therapeutics' stock price to reach $55.60 in the next twelve months. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Turning Point Therapeutics.
What is the consensus analysts' recommendation for Turning Point Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Turning Point Therapeutics.
Has Turning Point Therapeutics been receiving favorable news coverage?
Media headlines about TPTX stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Turning Point Therapeutics earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View News Stories for Turning Point Therapeutics.
Are investors shorting Turning Point Therapeutics?
Turning Point Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,110,000 shares, a decline of 6.6% from the January 15th total of 2,260,000 shares. Based on an average daily volume of 523,400 shares, the short-interest ratio is currently 4.0 days. Approximately 9.0% of the shares of the company are short sold. View Turning Point Therapeutics' Current Options Chain.
Who are some of Turning Point Therapeutics' key competitors?
Some companies that are related to Turning Point Therapeutics include Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO) and Arrowhead Pharmaceuticals (ARWR).
What other stocks do shareholders of Turning Point Therapeutics own?
Who are Turning Point Therapeutics' key executives?
Turning Point Therapeutics' management team includes the folowing people:
- Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)
- Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)
- Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)
- Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
- Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec.
When did Turning Point Therapeutics IPO?
(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.
Who are Turning Point Therapeutics' major shareholders?
Turning Point Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (13.50%), State Street Corp (2.88%), venBio Partners LLC (1.98%), Lord Abbett & CO. LLC (1.89%), Pictet Asset Management Ltd. (1.63%) and Alliancebernstein L.P. (1.53%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson. View Institutional Ownership Trends for Turning Point Therapeutics.
Which major investors are selling Turning Point Therapeutics stock?
TPTX stock was sold by a variety of institutional investors in the last quarter, including venBio Partners LLC, Perceptive Advisors LLC, Alyeska Investment Group L.P., Schonfeld Strategic Advisors LLC, SG Americas Securities LLC, Nicholas Investment Partners LP, Castleark Management LLC and UBS Group AG. View Insider Buying and Selling for Turning Point Therapeutics.
Which major investors are buying Turning Point Therapeutics stock?
TPTX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Jennison Associates LLC, Credit Suisse AG, AXA and Candriam Luxembourg S.C.A.. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George and Yi Larson. View Insider Buying and Selling for Turning Point Therapeutics.
How do I buy shares of Turning Point Therapeutics?
Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Turning Point Therapeutics' stock price today?
One share of TPTX stock can currently be purchased for approximately $60.00.
How big of a company is Turning Point Therapeutics?
What is Turning Point Therapeutics' official website?
How can I contact Turning Point Therapeutics?
Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]
MarketBeat Community Rating for Turning Point Therapeutics (NASDAQ TPTX)
MarketBeat's community ratings are surveys of what our community members think about Turning Point Therapeutics and other stocks. Vote "Outperform" if you believe TPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
